Compare DexCom, Inc. (DXCM) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

SCHD trades at $32.20, down 1.11% today, with a bullish technical signal from moving averages. The ETF has shown strong year-to-date performance, returning 17.50% according to Seeking Alpha on July 8, 2026, outperforming the S&P 500. Recent news highlights SCHD's exposure to AI stocks and its appeal for dividend-focused investors, though competition from higher-yielding international ETFs is noted.

SCHD presents a compelling opportunity for income investors seeking stable dividends and exposure to U.S. large-cap dividend payers. Risks include underperformance versus growth-focused ETFs in rising markets and pressure from higher Treasury yields. The ETF's low expense ratio and diversified holdings support its long-term appeal, but investors should monitor yield competitiveness and sector concentration.